Join us to build the future of drug discovery at Abata Therapeutics

South San Francisco, California, United States

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years), Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Drug Discovery, OncologyIndustries

Requirements

Solid background in single-cell bioinformatics on large atlas datasets
Solid background in machine learning applied to genomics data and cheminformatics
Solid background in high throughput synthetic lethal oncology genomics screens and subsequent target validation of individual genes
For Junior Scientists: experience with tissue culture, single-cell sample preparation, laboratory automation using robotics, and biochemical assays for target validation and mechanistic investigation
Background in medicinal chemistry, particularly in small molecule oncology
Resume/CV
Cover letter explaining the type of roles you'd be interested in

Responsibilities

Duties, responsibilities, and activities may change at any time with or without notice (specific responsibilities not comprehensively listed)

Skills

Single-cell bioinformatics

Machine learning

Genomics

Cheminformatics

High throughput screening

Synthetic lethal screens

Target validation

Tissue culture

Single-cell sample preparation

Laboratory automation

Robotics

Biochemical assays

Medicinal chemistry

Small molecule oncology

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free